1Dasgupta MK.Strategies for managing diabetic patients on peritoneal dialysis[J].Adv Perit Dial,2004,20:200-202.
2Kallio T,Nevalainen Pl.Hepatic subcapsular steatosis()in diabetic CAPD with intraperitoneal insulin.Description of a typical pattern[J].Acta Radiol,2001,42(3):323-325.
3Wild s,Roglie G,Green A,et al.Global prevalence fo diabetes:Estimates for the year 2000 and proiection for 2030.Diabetes Care,2004,27(3):1047-1053.
4Wild S, Roglic G, Green A, et al. A Global prevalence of diabetes:esti- mates for the year 2000 and projections for 2030 [J]. Diabetes Care,2004, 27:1047-1053.
5Alwakeel JS, Isnani AC, Alsuwaida A, et al. Factors affecting the pro- gression of diabetic nephropathy and its complications: a single-center experience in Saudi Arabia [J]. Ann Saudi Med,2011,31(3):236-242.
6Burgess E. Reviewing the benefits of angiotensin-converting enzyme in- hibitors and angiotensin receptor blockers in diabetic nephropathy are they drug specific or class specific [J]. Can J Cardiol,2010,26(1):lS-19.
9Glassock R J, Bleyer A J, Bargman J M, et al. The 2010 nephrology quizand questionnaire: part 2 [J]. Clin J Am Soc Nephrol, 2011, 6(10) :2534- 2547.
10Prakash J, Singh L K, Shreeniwas S, et al. Non-infectious complications of continuous ambulatory peritoneal dialysis and their impact on technique survival [J]. Indian J Nephrol, 2011, 21(2) :112-115.
